These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. Sharma A; Davis CB; Tobia LA; Kwok DC; Tucci MG; Gore ER; Herzyk DJ; Hart TK J Pharmacol Exp Ther; 2000 Apr; 293(1):33-41. PubMed ID: 10734150 [TBL] [Abstract][Full Text] [Related]
5. Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis. Roman J; Qiu J; Dornadula G; Hamuro L; Bakhtiar R; Verch T J Pharmacol Toxicol Methods; 2011; 63(3):227-35. PubMed ID: 21147239 [TBL] [Abstract][Full Text] [Related]
6. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Green JD; Black LE Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509 [TBL] [Abstract][Full Text] [Related]
7. HTPS flow cytometry: a novel platform for automated high throughput drug discovery and characterization. Edwards BS; Kuckuck FW; Prossnitz ER; Ransom JT; Sklar LA J Biomol Screen; 2001 Apr; 6(2):83-90. PubMed ID: 11689102 [TBL] [Abstract][Full Text] [Related]
8. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. Lappin PB; Black LE Toxicol Pathol; 2003; 31 Suppl():111-8. PubMed ID: 12597438 [TBL] [Abstract][Full Text] [Related]
9. Molecular pathology in the preclinical development of biopharmaceuticals. Gillett NA; Chan CM Toxicol Pathol; 1999; 27(1):48-52. PubMed ID: 10367673 [TBL] [Abstract][Full Text] [Related]
10. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Kon OM; Sihra BS; Compton CH; Leonard TB; Kay AB; Barnes NC Lancet; 1998 Oct; 352(9134):1109-13. PubMed ID: 9798587 [TBL] [Abstract][Full Text] [Related]
11. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Herzyk DJ; Gore ER; Polsky R; Nadwodny KL; Maier CC; Liu S; Hart TK; Harmsen AG; Bugelski PJ Infect Immun; 2001 Feb; 69(2):1032-43. PubMed ID: 11160000 [TBL] [Abstract][Full Text] [Related]
13. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Liang M; Schwickart M; Schneider AK; Vainshtein I; Del Nagro C; Standifer N; Roskos LK Cytometry B Clin Cytom; 2016 Mar; 90(2):117-27. PubMed ID: 26054054 [TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs. Flores MG; Zhang S; Ha A; Holm B; Reitz BA; Morris RE; Borie DC J Immunol Methods; 2004 Jun; 289(1-2):123-35. PubMed ID: 15251418 [TBL] [Abstract][Full Text] [Related]
15. A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development. Sternebring O; Alifrangis L; Christensen TF; Ji H; Hegelund AC; Högerkorp CM Cytometry B Clin Cytom; 2016 Mar; 90(2):220-9. PubMed ID: 26205127 [TBL] [Abstract][Full Text] [Related]
16. Disposition of metabolically radiolabeled CE9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4. Davis CB; Garver EM; Kwok DC; Urbanski JJ Drug Metab Dispos; 1996 Sep; 24(9):1032-7. PubMed ID: 8886616 [TBL] [Abstract][Full Text] [Related]
17. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance? Kooijman M; van Meer PJ; Moors EH; Schellekens H Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668 [TBL] [Abstract][Full Text] [Related]
18. Current laboratory practices in flow cytometry for the enumeration of CD 4(+) T-lymphocyte subsets. Whitby L; Whitby A; Fletcher M; Barnett D Cytometry B Clin Cytom; 2015; 88(5):305-11. PubMed ID: 25828263 [TBL] [Abstract][Full Text] [Related]
19. Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero. Herzyk DJ; Bugelski PJ; Hart TK; Wier PJ Hum Exp Toxicol; 2002; 21(9-10):507-12. PubMed ID: 12458908 [TBL] [Abstract][Full Text] [Related]
20. Preclinical assessments of european union marketing authorisation applications for immunomodulatory biopharmaceuticals. Liminga U Hum Exp Toxicol; 2000 Apr; 19(4):257-60. PubMed ID: 10918519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]